Cross-disorder GWAS meta-analysis of endocannabinoid DNA variations in major depressive disorder, bipolar disorder, attention deficit hyperactivity disorder, autism spectrum disorder, and schizophrenia.
Humans
Bipolar Disorder
/ genetics
Depressive Disorder, Major
/ genetics
Schizophrenia
/ genetics
Attention Deficit Disorder with Hyperactivity
/ genetics
Genome-Wide Association Study
Endocannabinoids
/ genetics
Autism Spectrum Disorder
/ genetics
Genetic Predisposition to Disease
DNA
Polymorphism, Single Nucleotide
/ genetics
Cross-disorder
Endocannabinoid system
GWAS, DAGLA, GABRA1
Mental disorder
Journal
Psychiatry research
ISSN: 1872-7123
Titre abrégé: Psychiatry Res
Pays: Ireland
ID NLM: 7911385
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
23
08
2023
revised:
19
10
2023
accepted:
25
10
2023
medline:
6
12
2023
pubmed:
5
11
2023
entrez:
4
11
2023
Statut:
ppublish
Résumé
The endocannabinoid system (ECS) is implicated in multiple mental disorders. In this study, we explored DNA variations in the ECS across major depressive disorder (MDD), bipolar disorder, attention deficit hyperactivity disorder (ADHD), autism spectrum disorder (ASD), and schizophrenia by performing a cross-disorder genome-wide association study (GWAS) meta-analysis. We obtained six datasets from the Psychiatric Genomics Consortium containing GWAS summary statistics from European cohorts (284,023 cases and 508,515 controls). Effective sample size weighted meta-analysis was performed for 2241 single nucleotide polymorphisms (SNPs) pertaining to gene bodies of 33 endocannabinoid genes using METAL, where an overall z-statistic is calculated for each marker based on a weighted sum of individual statistics. Heterogeneity was examined with I
Identifiants
pubmed: 37924773
pii: S0165-1781(23)00513-9
doi: 10.1016/j.psychres.2023.115563
pii:
doi:
Substances chimiques
Endocannabinoids
0
DNA
9007-49-2
Types de publication
Meta-Analysis
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
115563Informations de copyright
Copyright © 2023 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest MIH receives research support from the Brain and Behavior Research Foundation, Canadian Institutes of Health Research (CIHR), CAMH Foundation, the Physicians’ Services Incorporated (PSI) Foundation, and the University of Toronto. He has provided consultancy to Mindset Pharma, PsychEd Therapeutics, and Wake Network. He has led contracted research for COMPASS Pathways Ltd. DJM's research work is supported by the Canadian Institutes of Health Research (CIHR), the Ontario Brain Foundation, the Alternate Funding Plan of Ontario, and the Centre for Addiction and Mental Health Foundation. BHM holds and receives support from the Labatt Family Chair in Biology of Depression in Late-Life Adults at the University of Toronto. He currently receives or has received within the past five years research support from Brain Canada, the Canadian Institutes of Health Research, the CAMH Foundation, the Patient-Centered Outcomes Research Institute (PCORI), the US National Institute of Health (NIH), Capital Solution Design LLC (software used in a study founded by CAMH Foundation), and HAPPYneuron (software used in a study founded by Brain Canada). He has also been an unpaid consultant to Myriad Neuroscience. GZ's work has been supported by the Academic Scholar Award and the Labatt Family Innovation Fund in Brain Health, Department of Psychiatry, University of Toronto in addition to the Brain & Behavior Research Foundation, International Obsessive-Compulsive Disorder Foundation, and PSI Foundation in Ontario, Canada. SK's work has been supported by the Academic Scholar Award and the Labatt Family Innovation Fund in Brain Health, Department of Psychiatry, University of Toronto. SK has also received honorarium for past consultation from EmpowerPharm. HKK and VFG have no conflict of interest to disclose.